Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Andrew Ko
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02487277CT.gov PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pegph20 (this asset) | Andrew Ko | P2 | CCC · 53 |
| Cis-Diamminedichloroplatinum Ii | Mayo Clinic | P4 | BBB |
| Carboplatin | Blueprint Medicines Corporation | P4 | BBB |
| Irinotecan | University of Chicago | P2 | BBB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P3 | BB |
| Icotinib | Betta Pharmaceuticals Co., Ltd. | P4 | BB |
| Desflurane | University of Zurich | P4 | BB |
| Fluorouracilum | University of Chicago | P2 | BB |
| Capecitabine | Fudan University | P2 | BB |
+42 more in the Adenocarcinoma cohort
Other indications for Pegph20
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Pancreatic Neoplasm | — | P2 | B · 61 |
| Pancreatic Ductal Adenocarcinoma | — | P2 | CCC · 53 |
| Pancreatic Adenocarcinoma | — | P1/2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pegph20 in Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pegph20-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →